Cargando…
How COVID-19 induces cytokine storm with high mortality
The newly emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but has rapidly spread all over the world. Some COVID-19 patients encounter a severe symptom of acute respiratory distress syndrome (ARDS)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527296/ https://www.ncbi.nlm.nih.gov/pubmed/33014208 http://dx.doi.org/10.1186/s41232-020-00146-3 |
_version_ | 1783589025671544832 |
---|---|
author | Hojyo, Shintaro Uchida, Mona Tanaka, Kumiko Hasebe, Rie Tanaka, Yuki Murakami, Masaaki Hirano, Toshio |
author_facet | Hojyo, Shintaro Uchida, Mona Tanaka, Kumiko Hasebe, Rie Tanaka, Yuki Murakami, Masaaki Hirano, Toshio |
author_sort | Hojyo, Shintaro |
collection | PubMed |
description | The newly emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but has rapidly spread all over the world. Some COVID-19 patients encounter a severe symptom of acute respiratory distress syndrome (ARDS) with high mortality. This high severity is dependent on a cytokine storm, most likely induced by the interleukin-6 (IL-6) amplifier, which is hyper-activation machinery that regulates the nuclear factor kappa B (NF-κB) pathway and stimulated by the simultaneous activation of IL-6-signal transducer and activator of transcription 3 (STAT3) and NF-κB signaling in non-immune cells including alveolar epithelial cells and endothelial cells. We hypothesize that IL-6-STAT3 signaling is a promising therapeutic target for the cytokine storm in COVID-19, because IL-6 is a major STAT3 stimulator, particularly during inflammation. We herein review the pathogenic mechanism and potential therapeutic targets of ARDS in COVID-19 patients. |
format | Online Article Text |
id | pubmed-7527296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75272962020-10-01 How COVID-19 induces cytokine storm with high mortality Hojyo, Shintaro Uchida, Mona Tanaka, Kumiko Hasebe, Rie Tanaka, Yuki Murakami, Masaaki Hirano, Toshio Inflamm Regen Review The newly emerging coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, but has rapidly spread all over the world. Some COVID-19 patients encounter a severe symptom of acute respiratory distress syndrome (ARDS) with high mortality. This high severity is dependent on a cytokine storm, most likely induced by the interleukin-6 (IL-6) amplifier, which is hyper-activation machinery that regulates the nuclear factor kappa B (NF-κB) pathway and stimulated by the simultaneous activation of IL-6-signal transducer and activator of transcription 3 (STAT3) and NF-κB signaling in non-immune cells including alveolar epithelial cells and endothelial cells. We hypothesize that IL-6-STAT3 signaling is a promising therapeutic target for the cytokine storm in COVID-19, because IL-6 is a major STAT3 stimulator, particularly during inflammation. We herein review the pathogenic mechanism and potential therapeutic targets of ARDS in COVID-19 patients. BioMed Central 2020-10-01 /pmc/articles/PMC7527296/ /pubmed/33014208 http://dx.doi.org/10.1186/s41232-020-00146-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Hojyo, Shintaro Uchida, Mona Tanaka, Kumiko Hasebe, Rie Tanaka, Yuki Murakami, Masaaki Hirano, Toshio How COVID-19 induces cytokine storm with high mortality |
title | How COVID-19 induces cytokine storm with high mortality |
title_full | How COVID-19 induces cytokine storm with high mortality |
title_fullStr | How COVID-19 induces cytokine storm with high mortality |
title_full_unstemmed | How COVID-19 induces cytokine storm with high mortality |
title_short | How COVID-19 induces cytokine storm with high mortality |
title_sort | how covid-19 induces cytokine storm with high mortality |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527296/ https://www.ncbi.nlm.nih.gov/pubmed/33014208 http://dx.doi.org/10.1186/s41232-020-00146-3 |
work_keys_str_mv | AT hojyoshintaro howcovid19inducescytokinestormwithhighmortality AT uchidamona howcovid19inducescytokinestormwithhighmortality AT tanakakumiko howcovid19inducescytokinestormwithhighmortality AT haseberie howcovid19inducescytokinestormwithhighmortality AT tanakayuki howcovid19inducescytokinestormwithhighmortality AT murakamimasaaki howcovid19inducescytokinestormwithhighmortality AT hiranotoshio howcovid19inducescytokinestormwithhighmortality |